3
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
8
Polycythemia Vera
6
Multiple Myeloma
5
Prostatic Neoplasms
4
Neoplasms
4
Colonic Neoplasms
4
Cardiovascular Diseases
4
Venous Thromboembolism
3
Thrombocythemia, Essential
3
Precancerous Conditions
3
Ovarian Neoplasms
3
Neoplasms, Plasma Cell
3
Myeloproliferative Disorders
3
Melanoma
3
Esophageal Neoplasms
3
Barrett Esophagus
3
Tobacco Use Disorder
2
Thrombosis
2
Thromboembolism
2
Stomach Neoplasms
2
Rectal Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Adenomatous Polyps
2
Vascular Diseases
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Stroke
1
Interventions
Oxaliplatin
14
Fluorouracil
11
Capecitabine
9
Surveys and Questionnaires
8
Leucovorin
8
Irinotecan
8
Cisplatin
8
Bevacizumab
8
Standard of Care
5
Gemcitabine
5
Drug Therapy
4
S 1 (combination)
3
Radiotherapy
3
Nivolumab
3
Interviews as Topic
3
IFL protocol
3
Educational Status
3
Cyclophosphamide
3
Colonoscopy
3
Blood Specimen Collection
3
5,10-methylenetetrahydrofolic acid
3
trebananib
2
tivozanib
2
pembrolizumab
2
Taxes
2
Remote Patient Monitoring
2
Pemetrexed
2
Panitumumab
2
Ocoxin
2
N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gastrointestinal Neoplasms
×
Aspirin
×
Clear all
NCT04081831
2022-04-19
ENgAGE-HK
Bayer
Completed
99,999 enrolled